Salivary Gland Cancer

Bland cytomorphological features typical of fusion-associated neoplasms do not preclude presence of aggressive histological features and development of recurrence in MSA. These aggressive features may serve as indicators for escalation of treatment, despite the low-grade appearance of MSA.

Intraoperative frozen section examination indicated a pathological diagnosis of low-grade malignant salivary gland tumor. Thus, comprehensive histopathological and molecular analyses are essential, as the morphological features of this tumor may be deceptively bland.

Parotid oncocytomas in BHDS demonstrate distinctive clinicopathologic features, including younger patient age, cytoplasmic clearing, and a characteristic GPNMB-positive immunophenotype. These findings distinguish them from sporadic parotid oncocytomas and support the use of GPNMB as a potential adjunct marker to raise suspicion for BHDS. Recognition of this association is clinically significant, as patients with BHDS have an estimated 15-30% risk of developing renal malignancies, including chromophobe renal cell carcinoma and clear cell renal cell carcinoma, underscoring the importance of early diagnosis and appropriate surveillance.

P2, N=21, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2027 --> Nov 2026 | Trial primary completion date: Apr 2027 --> Nov 2026

CNS involvement in ACC was associated with poor outcomes despite multimodal therapy. NOTCH1 alterations and leptomeningeal disease were frequent in this cohort, but these findings should be interpreted as hypothesis-generating given the small sample size and absence of a matched non-CNS comparator cohort.

These findings may represent a previously undescribed type of salivary gland tumor. However, additional reports of similar lesions are necessary for definitive characterization.

ETV6-NTRK3 gene translocation is the most reliable basis for diagnosing SC. Combining morphological diagnosis with gene testing is not difficult.

Our study summarizes and updates the clinical features of EMC arising from palatal MSGs. CRD42024542994.

Given the advanced stage, the patient received a systemic combination of tislelizumab, cyclophosphamide, pegylated liposomal doxorubicin, and nedaplatin, initially combined with local intrapleural therapy. This case highlights a diagnostic pitfall in lung tumors exhibiting squamoid immunophenotypes and underscores the necessity of incorporating myoepithelial markers into the diagnostic workup. Furthermore, it provides a cautiously interpreted clinical observation of immune checkpoint inhibitor-based combination therapy in advanced PACC.

P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026

A more definitive diagnosis of NF can be established on cytological material using ancillary studies, particularly in situ hybridization (ISH) analysis for USP6 rearrangement, thereby guiding more appropriate clinical management. This report aims to highlight this important diagnostic pitfall and alert cytopathologists by providing an illustrative example.

This study provides new insights into the clinicopathological and molecular features of WL-MEC, confirming its typical presentation (parotid gland, middle-aged females), low-grade behavior, and favorable prognosis after surgical excision. Detection of MAML2 rearrangement is a valuable diagnostic tool for distinguishing WL-MEC from WT.